Sequestration of Inflammation in Parkinson's Disease via Stem Cell Therapy.
Jonah GordonGavin Miles LockardMolly MonsourAdam AlayliHassan ChoudharyCesario Venturina BorlonganPublished in: International journal of molecular sciences (2022)
Parkinson's disease is the second most common neurodegenerative disease. Insidious and progressive, this disorder is secondary to the gradual loss of dopaminergic signaling and worsening neuroinflammation, affecting patients' motor capabilities. Gold standard treatment includes exogenous dopamine therapy in the form of levodopa-carbidopa, or surgical intervention with a deep brain stimulator to the subcortical basal ganglia. Unfortunately, these therapies may ironically exacerbate the already pro-inflammatory environment. An alternative approach may involve cell-based therapies. Cell-based therapies, whether endogenous or exogenous, often have anti-inflammatory properties. Alternative strategies, such as exercise and diet modifications, also appear to play a significant role in facilitating endogenous and exogenous stem cells to induce an anti-inflammatory response, and thus are of unique interest to neuroinflammatory conditions including Parkinson's disease. Treating patients with current gold standard therapeutics and adding adjuvant stem cell therapy, alongside the aforementioned lifestyle modifications, may ideally sequester inflammation and thus halt neurodegeneration.
Keyphrases
- cell therapy
- stem cells
- mesenchymal stem cells
- inflammatory response
- oxidative stress
- physical activity
- metabolic syndrome
- anti inflammatory
- end stage renal disease
- weight loss
- multiple sclerosis
- newly diagnosed
- ejection fraction
- randomized controlled trial
- type diabetes
- bone marrow
- lps induced
- parkinson disease
- chronic kidney disease
- traumatic brain injury
- early stage
- peritoneal dialysis
- resting state
- toll like receptor
- body composition
- subarachnoid hemorrhage
- combination therapy
- smoking cessation